Why a onetime biotech IPO hopeful shifted to a 'blank check' deal By: San Francisco Business Times via Business Journals November 08, 2021 at 18:02 PM EST The company's lead drug targets a deadly lung-scarring disease and could start a mid-stage clinical trial in the first half of next year. Read More >>
